Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma-Reference-Cited by-同舟云学术

Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma

Published:2020-06-12 Issue:24 Volume:6 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

da Silva Adriana L.¹²^ORCID,de Oliveira Gisele P.¹^ORCID,Kim Namho³⁴^ORCID,Cruz Fernanda F.¹^ORCID,Kitoko Jamil Z.⁵^ORCID,Blanco Natalia G.¹^ORCID,Martini Sabrina V.²^ORCID,Hanes Justin³⁴⁶^ORCID,Rocco Patricia R. M.¹^ORCID,Suk Jung Soo³⁴⁶^ORCID,Morales Marcelo M.²^ORCID

Affiliation:

1. Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.

2. Laboratory of Cellular and Molecular Physiology, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.

3. Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

4. Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.

5. Laboratory of Inflammation and Immunity, Paulo de Góes Institute of Microbiology, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.

6. Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Abstract

Nanoparticle-based thymulin gene therapy provides near-complete resolution of key pathology of chronic allergic asthma.

Funder

National Heart, Lung, and Blood Institute

National Eye Institute

Cystic Fibrosis Foundation

Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

Center of Excellence Program

Brazilian Council for Scientific and Technological Development

Publisher

American Association for the Advancement of Science (AAAS)